Latest On Genomma Lab Internacional, S.A.B. de C.V (GNMLF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-06-20 06:08 EST | Dividend | A dividend of $0.2 has been announced on Jun 13, 2024. It will be paid Jun 21, 2024 with an ex-dividend date of Jun 20, 2024. | Neutral |  |
| 2023-12-22 05:07 EST | Dividend | A dividend of $0.2 has been announced on Dec 13, 2023. It will be paid Dec 27, 2023 with an ex-dividend date of Dec 22, 2023. | Neutral | |
| 2023-09-27 06:08 EST | Dividend | A dividend of $0.2 has been announced on Sep 19, 2023. It will be paid Sep 29, 2023 with an ex-dividend date of Sep 27, 2023. | Neutral | |
| 2023-06-05 06:08 EST | Dividend | A dividend of $0.2 has been announced on May 29, 2023. It will be paid Jun 7, 2023 with an ex-dividend date of Jun 5, 2023. | Neutral | |
| 2022-11-09 05:09 EST | Dividend | A dividend of $0.38 has been announced on Oct 26, 2022. It will be paid Nov 11, 2022 with an ex-dividend date of Nov 9, 2022. | Neutral | |
| 2022-06-06 06:06 EST | Dividend | A dividend of $0.38 has been announced on May 30, 2022. It will be paid Jun 8, 2022 with an ex-dividend date of Jun 6, 2022. | Neutral | |
| 2022-04-28 07:57 EST | News | Genomma Lab Internacional, S.A.B. de C.V. reports Q1 results | N/A | |
| 2022-02-25 02:37 EST | News | Genomma Lab Internacional, S.A.B. de C.V. reports Q4 results | N/A | |
| 2021-12-08 05:08 EST | Dividend | A dividend of $0.38 has been announced on Nov 26, 2021. It will be paid Dec 10, 2021 with an ex-dividend date of Dec 8, 2021. | Neutral | |
| 2021-12-01 05:09 EST | Dividend | A dividend of $0.76 has been announced on Nov 25, 2021. It will be paid Dec 3, 2021 with an ex-dividend date of Dec 1, 2021. | Neutral | |
| 2021-11-19 05:10 EST | News | Oramed, Genomma Lab joint venture to commercialize oral COVID vaccine in Mexico | N/A | |
| 2021-03-12 09:52 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-27 09:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 18:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 19:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 06:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-22 13:09 EST | News | Genomma Lab Internacional, S.A.B. de C.V. reports Q3 results | N/A | |
| 2020-10-08 20:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 03:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 03:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 23:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 15:52 EST | News | Genomma Lab Internacional, S.A.B. de C.V. reports Q2 results | N/A | |
| 2020-07-09 12:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 06:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 18:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 08:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:17 EST | Financials | Company financials have been released. | Neutral | |
About Genomma Lab Internacional, S.A.B. de C.V (GNMLF):
Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the research, development, and marketing of pharmaceutical, over the counter, and personal care products in Mexico, the United States, and Latin America. It offers antibacterial products under the Next-AB brand name, including disinfecting wet wipes, alcohol-based hand sanitizers, and antibacterial soaps; razor products under the Groomen brand; anti-flu medicines under the Next brand; HIV testing kits under the OraQuick brand name; and isotonic beverages under the Suerox brand, as well as gold lift creams under the Cicatricure brand. The company also provides shampoos under the Revie, Vanart, and TÃo Nacho names; and cough and cold medicines under the Tukol brand. Genomma Lab Internacional, S.A.B. de C.V. was founded in 1996 and is based in Mexico City, Mexico.
General
- Name Genomma Lab Internacional, S.A.B. de C.V
- Symbol GNMLF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 1,305
- Fiscal Year EndDecember
- Web URLhttp://www.genommalab.com
View More
Valuation
- Trailing PE 15.15
- Forward PE 12.42
- Price/Sales (Trailing 12 Mt.) 1.63
- Price/Book (Most Recent Quarter) 2.38
- Enterprise Value Revenue 0.09
- Enterprise Value EBITDA 0.43
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 11%
- Return on Assets 8%
- Return on Equity 17%
- Revenue Per Share $0
- Gross Profit 8.59 billion
- Quarterly Earnings Growth 7.7%
View More
Highlights
- Market Capitalization 1.08 billion
View More
Share Statistics
- Shares Outstanding 1.02 billion
- Shares Float 709.89 million
- % Held by Insiders 2820%
- % Held by Institutions 30.14%
View More
Technicals
- Beta 0.51
- 52 Week High $2
- 52 Week Low $0.76
- 50 Day Moving Average 4.55
- 200 Day Moving Average 1.84
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Genomma Lab Internacional, S.A.B. de C.V (GNMLF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Genomma Lab Internacional, S.A.B. de C.V (GNMLF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $3.43 billion | $0.02 | $0.33 | -94.97% |
| 2020-06-30 | 2020-09-30 | $3.64 billion | $0.02 | $0.36 | -94.97% |
| 2020-03-31 | 2020-06-30 | $3.33 billion | $0.02 | $0.32 | -95.09% |
| 2019-12-31 | 2020-03-31 | $3.26 billion | $0.02 | $0.28 | -94.43% |
| 2019-09-30 | 2019-12-31 | $3.08 billion | $0.00 | $0.28 | -99.36% |
| 2019-06-30 | 2019-09-30 | $3.28 billion | $0.01 | $0.29 | -95.97% |
| 2019-03-31 | 2019-06-30 | $3.14 billion | $0.01 | $0.27 | -95.37% |
| 2018-12-31 | 2019-03-31 | $3.12 billion | $0.01 | $0.22 | -94.14% |
| 2018-09-30 | 2018-12-31 | $2.73 billion | $0.01 | $0.32 | -97.94% |
| 2018-06-30 | 2018-09-30 | $3.1 billion | $0.01 | $0.31 | -95.87% |
| 2018-03-31 | 2018-06-30 | $3.03 billion | $0.02 | $0.41 | -96.07% |
| 2017-12-31 | 2018-03-31 | $2.89 billion | $0.02 | $0.31 | -93.06% |
| 2017-09-30 | 2017-12-31 | $168.91 million | $0.02 | $0.35 | -94.89% |
| 2017-06-30 | 2017-09-30 | $2.91 billion | $0.01 | $0.37 | -96.43% |
| 2017-03-31 | 2017-06-30 | $3.2 billion | $0.02 | $0.31 | -94.84% |
| 2016-12-31 | 2017-03-31 | $0.02 | $0.42 | -94.14% | |
| 2016-09-30 | 2016-12-31 | $2.92 billion | $0.00 | $0.29 | -99.69% |
| 2016-06-30 | 2016-09-30 | $0.03 | $0.25 | -89.88% | |
| 2016-03-31 | 2016-06-30 | -$0.14 | $0.18 | -176% | |
| 2015-12-31 | 2016-03-31 | $0.02 | $0.29 | -92.97% | |
| 2015-09-30 | 2015-12-31 | -$0.10 | $0.36 | -127.14% | |
| 2015-06-30 | 2015-09-30 | $0.01 | $0.29 | -96.55% | |
| 2015-03-31 | 2015-06-30 | $0.02 | $0.20 | -90.25% | |
| 2014-12-31 | 2015-03-31 | $0.01 | $0.83 | -99.12% | |
| 2014-09-30 | 2014-10-24 | $0.45 | $0.51 | -11.76% | |
| 2014-06-30 | 2014-09-30 | $0.03 | $0.32 | -89.5% | |
| 2014-03-31 | 2014-06-30 | $0.02 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.01 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.06 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.03 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.02 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.01 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.06 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.03 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.02 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.01 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.04 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.03 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.02 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.04 | $0.00 |
Genomma Lab Internacional, S.A.B. de C.V (GNMLF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | 566.89 million | 609.1 million | 579.71 million | 384 million |
| Selling General Administrative | N/A | 1.42 billion | 1.43 billion | 1.38 billion | 1.48 billion |
| Gross Profit | N/A | 2.19 billion | 2.18 billion | 2.06 billion | 2.06 billion |
| Ebit | N/A | 726.97 million | 762.76 million | 747.67 million | 623.13 million |
| Operating Income | N/A | 731.66 million | 714.86 million | 639.31 million | 623.13 million |
| Income Tax Expense | 157129 | 157.75 million | 248.29 million | 206.07 million | 126.11 million |
| Total Revenue | N/A | 3.43 billion | 3.64 billion | 3.33 billion | 3.26 billion |
| Cost of Revenue | N/A | 1.24 billion | 1.46 billion | 1.27 billion | 1.21 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -239.13 million |
| Net Income From Continuing Operations | N/A | 409.14 million | 360.82 million | 373.63 million | 257.88 million |
| Net Income Applicable to Common Shares | 334214 | 409.14 million | 360.82 million | 373.63 million | 257.88 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -136.31 million | -136.31 million | N/A | -168 million |
| Change to Liabilities | -107.82 million | 149.24 million | -164.89 million | -30.32 million | 25.62 million |
| Total Cash Flow from Investing Activities | -166.07 million | -136.2 million | -136.31 million | -370.43 million | -126.25 million |
| Net Borrowings | 306 million | 8.69 million | 136.14 million | 658.87 million | -716.48 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -128.21 million | -298.17 million |
| Change to Operating Activities | -38.4 million | -46.99 million | 875.98 million | 202.33 million | -333.89 million |
| Change in Cash | N/A | 437 million | 437 million | -210.25 million | -11.81 million |
| Total Cash from Operating Activities | 343.13 million | 565.61 million | 565.61 million | 279.33 million | 412.65 million |
| Depreciation | N/A | 38.67 million | 38.67 million | 39.59 million | 37.19 million |
| Other Cash Flow from Investing Activities | -705000 | 11.56 million | 14.65 million | -6.06 million | -8.17 million |
| Change to Inventory | N/A | -201.46 million | -201.46 million | 6.28 million | -98.75 million |
| Change to Account Receivables | N/A | N/A | N/A | -353.77 million | 155.28 million |
| Other Cash Flow from Financing Activities | -103.12 million | -112.04 million | -125.13 million | -187.08 million | -149.89 million |
| Change to Net Income | 222.1 million | -8.47 million | 256.74 million | 157.33 million | 393.81 million |
| Capital Expenditures | N/A | 158.37 million | 158.37 million | 333.99 million | 117.07 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 12.45 billion | 12.16 billion | 12.22 billion | 11.09 billion |
| Total Stockholder Equity | N/A | 9.33 billion | 8.94 billion | 8.68 billion | 8.24 billion |
| Other Current Liabilities | 2.96 million | 2.77 billion | 2.65 billion | 2.6 billion | 2.09 billion |
| Total Assets | N/A | 21.78 billion | 21.1 billion | 20.91 billion | 19.33 billion |
| Common Stock | 1.91 million | 1.91 billion | 1.91 billion | 1.91 billion | 1.91 billion |
| Other Current Assets | N/A | 424.62 million | N/A | N/A | 681.36 million |
| Retained Earnings | 8.88 million | 8.74 billion | 8.27 billion | 7.97 billion | 7.31 billion |
| Other Liabilities | 1.32 million | 1.16 billion | 1.19 billion | 1.34 billion | 929.67 million |
| Other Assets | 729479 | 646.71 million | 620.56 million | 639.35 million | 601.88 million |
| Cash | N/A | 1.57 billion | 1.19 billion | 1.35 billion | 922.95 million |
| Total Current Liabilities | 6.56 million | 6.65 billion | 9.23 billion | 6.61 billion | 5.63 billion |
| Other Stockholder Equity | -22359 | 600.39 million | 670.54 million | 711.1 million | 494.6 million |
| Property, Plant & Equipment | 2.8 million | 2.58 billion | 2.47 billion | 2.32 billion | 2.26 billion |
| Total Current Assets | 11.89 million | 11.88 billion | 11.32 billion | 11.28 billion | 9.99 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 1.6 billion |
| Net Tangible Assets | 4.79 million | 4.22 billion | 3.9 billion | 3.63 billion | 3.37 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | 4.63 billion | 1.72 billion | 4.23 billion | 4.48 billion |
| Inventory | 2 million | 2.27 billion | 2.19 billion | 2.07 billion | 1.9 billion |
| Accounts Payable | 1.63 million | 1.75 billion | 1.86 billion | 1.71 billion | 1.87 billion |
Genomma Lab Internacional, S.A.B. de C.V (GNMLF) Chart:
Genomma Lab Internacional, S.A.B. de C.V (GNMLF) News:
Below you will find a list of latest news for Genomma Lab Internacional, S.A.B. de C.V (GNMLF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Genomma Lab Internacional, S.A.B. de C.V (GNMLF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Genomma Lab Internacional, S.A.B. de C.V (GNMLF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|